Pulmonary Arterial Hypertension: Molecular Genetic Basis and Emerging Treatments

Authors

  • MA Siddiqui Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
  • Takeshi Ogo Dept of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre
  • MT Nasim National Institute for Health Research (NIHR), Biomedical Research Centre, Guy's and St. Thomas' NHS Foundation Trust and King's College London, London, United Kingdom

DOI:

https://doi.org/10.3329/akmmcj.v3i2.11691

Keywords:

PAH, Genetic basis, Emerging treatment

Abstract

Pulmonary arterial hypertension (PAH) is a rare cardiovascular disorder caused by narrowing of blood vessels in the lung and in the absence of therapy leads to right heart failure and death. No cure for this devastating disorder is known. The major objective of the current treatments is to improve symptoms and these therapies were developed prior to the discovery that this disease has substantial genetic components. In this review, we discuss molecular      genetic basis of PAH together with pathobiology, current and future therapeutic interventions.

 

DOI: http://dx.doi.org/10.3329/akmmcj.v3i2.11691

 

AKMMC J 2012; 3(2): 30-33

 

Downloads

Download data is not yet available.
Abstract
834
PDF
710

Downloads

Published

2012-08-27

How to Cite

Siddiqui, M., Ogo, T., & Nasim, M. (2012). Pulmonary Arterial Hypertension: Molecular Genetic Basis and Emerging Treatments. Anwer Khan Modern Medical College Journal, 3(2), 30–33. https://doi.org/10.3329/akmmcj.v3i2.11691

Issue

Vol. 3 No. 2 (2012)

Section

Review Articles